Long-acting injectables and risk for rehospitalization among patients with schizophrenia in the home care program in Taiwan

Journal of Clinical Psychopharmacology

Volumn 34, Issue 1, 2014, Pages 23-29

  Ju, Po Chung ^a,b   Chou, Frank Huang Chih ^c,d   Lai, Te Jen ^a,b   Chuang, Po Ya ^e   Lin, Yung Jung ^f   Yang, Ching Wen Wendy ^g   Tang, Chao Hsiun ^e  

^a Chung Shan Medical University Hospital   (Japan)

^b CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

^c Superintendent of Kaohsiung Kai Syuan Psychiatric Hospital   (Taiwan)

^d MEIHO UNIVERSITY   (Taiwan)

^e TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^f Janssen Cilag Taiwan   (Taiwan)

^g UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Home care; Logistic regression; Long acting injection; Risperidone; Schizophrenia

Indexed keywords

NEUROLEPTIC AGENT; RISPERIDONE;

ADULT; ARTICLE; FEMALE; HOME MENTAL HEALTH CARE; HOSPITAL DISCHARGE; HOSPITAL READMISSION; HUMAN; ICD-9-CM; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NATIONAL HEALTH INSURANCE; POPULATION RESEARCH; PRESCRIPTION; PRIORITY JOURNAL; RISK ASSESSMENT; SCHIZOPHRENIA; TAIWAN; THERAPY EFFECT;

ADMINISTRATION, ORAL; ADULT; ANTIPSYCHOTIC AGENTS; CHEMISTRY, PHARMACEUTICAL; DELAYED-ACTION PREPARATIONS; FEMALE; HOME CARE SERVICES, HOSPITAL-BASED; HUMANS; INJECTIONS; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; PATIENT READMISSION; PROGRAM EVALUATION; PROPENSITY SCORE; RECURRENCE; RISK FACTORS; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; TAIWAN; TIME FACTORS; TREATMENT OUTCOME;

EID: 84891735927     PISSN: 02710749     EISSN: 1533712X     Source Type: Journal    
DOI: 10.1097/JCP.0b013e3182a6a142     Document Type: Article

References (38)

1. Tarricone R, Gerzeli S, Montanelli R, et al. Direct and indirect costs of schizophrenia in community psychiatric services in Italy. The GISIES study. Interdisciplinary Study Group on the Economic Impact of Schizophrenia. Health Policy. 2000;51:1-18.
2. Andrews G, Hall W, Goldstein G, et al. The economic costs of schizophrenia. Implications for public policy. Arch Gen Psychiatry. 1985;42:537-543.
3. Burns T, Raftery J. Cost of schizophrenia in a randomized trial of home-based treatment. Schizophr Bull. 1991;17:407-410.
4. Wasylenki DA. The cost of schizophrenia. Can J Psychiatry. 1994;39 (9 suppl 2):S65-S69.
5. Ko SY, Chen PS, Yang YK, et al. Correlation between performance on the Continuous Performance Test and economic costs in patients with schizophrenia. Psychiatry Clin Neurosci. 2003;57:373-377.
6. Rund BR, Rund T. Costs of services for schizophrenic patients in Norway. Acta Psychiatr Scand. 1999;99:120-125.
7. Knoll JL 4th, Garver DL, Ramberg JE, et al. Heterogeneity of the psychoses: is there a neurodegenerative psychosis? Schizophr Bull. 1998;24:365-379.
8. Yang YK, Tarn YH, Wang TY, et al. Pharmacoeconomic evaluation of schizophrenia in Taiwan: model comparison of long-acting risperidone versus olanzapine versus depot haloperidol based on estimated costs. Psychiatry Clin Neurosci. 2005;59:385-394.
9. Knapp M. Schizophrenia costs and treatment cost-effectiveness. Acta Psychiatr Scand Suppl. 2000;407:15-18.
10. Dolder CR, Lacro JP, Dunn LB, et al. Antipsychotic medication adherence: is there a difference between typical and atypical agents? Am J Psychiatry. 2002;159:103-108.
11. Marder SR. Facilitating compliance with antipsychotic medication. J Clin Psychiatry. 1998;59(suppl 3):21-25.
12. Huffman JC, Blais MA, Pirl WF. A comparison of clinician and patient concerns about antipsychotic side effects: a pilot study. J Nerv Ment Dis. 2004;192:328-330.
13. Barbui C, Nose M, Bindman J, et al. Sex differences in the subjective tolerability of antipsychotic drugs. J Clin Psychopharmacol. 2005; 25:521-526.
14. Nose M, Mazzi MA, Esposito E, et al. Adverse effects of antipsychotic drugs: survey of doctors' versus patients' perspective. Soc Psychiatry Psychiatr Epidemiol. 2012;47:157-164.
15. Fenton WS, Blyler CR, Heinssen RK. Determinants of medication compliance in schizophrenia: empirical and clinical findings. Schizophr Bull. 1997;23:637-651.
16. Larco JP, Dunn LB, Dolder CR, et al. Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. J Clin Psychiatry. 2002; 63:892-909.
17. Davis A, Matalon L, Watanabe MD, et al. Depot antipsychotic drugs: place in therapy. Drugs. 1994;47:741-773.
18. Perkins DO. Predictors of noncompliance in patients with schizophrenia. J Clin Psychiatry. 2002;63:1121-1128.
19. Glazer WM, Ereshefsky L. A pharmacoeconomic model of outpatient antipsychotic therapy in ''revolving door'' schizophrenic patients. J Clin Psychiatry. 1996;57:337-345.
20. Adams CE, Fenton MK, Quraishi S, et al. Systematic meta-review of depot antipsychotic drugs for people with schizophrenia. Br J Psychiatry. 2001;179:290-299.
21. Kane JM, Eerdekens M, Lindenmayer JP, et al. Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic. Am J Psychiatry. 2003;160:1125-1132.
22. Kelleher JP, Centorrino F, Albert MJ, et al. Advances in atypical antipsychotics for the treatment of schizophrenia: new formulations and new agents. CNS Drugs. 2002;16:249-261.
23. Fleischhacker WW, Eerdekens M, Karcher K, et al. Treatment of schizophrenia with long-acting injectable risperidone: a 12-month open-label trial of the first long-acting second-generation antipsychotic. J Clin Psychiatry. 2003;64:1250-1257.
24. Mohit DL. Management and care of mentally ill mothers of young children: an innovative program. Arch Psychiatr Nurs. 1996;10:49-54.
25. Morris M. Patients' perceptions of psychiatric home care. Arch Psychiatr Nurs. 1996;10:176-183.
26. Zhang WH, Zhou MC, Hu HM. The investigation of home care program of schizophrenia in rural area. J Clin Psychiatry. 1994;4:96-97.
27. National Health Insurance Research Database, Taiwan. Background: National Health Insurance Research Database. Available at: http://w3.nhri.org.tw/nhird/ en/index.htm. Accessed June 24, 2012.
28. Tang CH, Hsieh MH, Hung ST, et al. One-year post-hospital medical costs and relapse rates of bipolar disorder patients in Taiwan: a population-based study. Bipolar Disord. 2010;12:859-865.
29. Rosenbaum PR, Rubin DB. Reducing bias in observational studies using subclassification on the propensity score. J Am Stat Assoc. 1984;79:516-524.
30. D'Agostino RB Jr. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med. 1998;17:2265-2281.
31. Lasser RA, Bossie CA, Gharabawi GM, et al. Patients with schizophrenia previously stabilized on conventional depot antipsychotics experience significant clinical improvements following treatment with long-acting risperidone. Eur Psychiatry. 2004;19:219-225.
32. Barnes TR, Curson DA. Long-term depot antipsychotics. A risk-benefit assessment. Drug Saf. 1994;10:464-479.
33. Bai YM, Ting Chen T, Chen JY, et al. Equivalent switching dose from oral risperidone to risperidone long-acting injection: a 48-week randomized, prospective, single-blind pharmacokinetic study. J Clin Psychiatry. 2007;68:1218-1225.
34. Lasser RA, Bossie CA, Gharabawi GM, et al. Clinical improvement in 336 stable chronically psychotic patients changed from oral to long-acting risperidone: a 12-month open trial. Int J Neuropsychopharmacol. 2005;8:427-438.
35. Bai YM, Chen TT,Wu B, et al. A comparative efficacy and safety study of long-acting risperidone injection and risperidone oral tablets among hospitalized patients: 12-week randomized, single-blind study. Pharmacopsychiatry. 2006;39:135-141.
36. Schmauss M, Sacchetti E, Kahn JP, et al. Efficacy and safety of risperidone long-acting injectable in stable psychotic patients previously treated with oral risperidone. Int Clin Psychopharmacol. 2007;22:85-92.
37. Kane JM, Aguglia E, Altamura AC, et al. Guidelines for depot antipsychotic treatment in schizophrenia. European Neuropsychopharmacology Consensus Conference in Siena, Italy. Eur Neuropsychopharmacol. 1998;8:55-66.
38. Marder SR, Midha KK, Van Putten T, et al. Plasma levels of fluphenazine in patients receiving fluphenazine decanoate: relationship to clinical response. Br J Psychiatry. 1991;158:658-665.